SK Biopharm, 2,252,102 Shares Net Bought by Individuals in Last 5 Days... Stock Price 159,500 KRW (-0.62%)

As of 2:31 PM on the 6th, SK Biopharm is trading at 159,500 KRW, down 0.62% from the previous day. The trading volume is 522,799 shares, which is about 38.38% of the previous day's volume.

On January 4th, researcher Han Byunghwa from Eugene Investment & Securities stated, "The global market expansion of Cenobamate is underway. As the indication for the main drug Cenobamate expands from partial seizures to generalized seizures in the U.S. market, sales are expected to surge. Starting in 2025, sales of Carisbamate, a treatment for Lennox-Gastaut syndrome, will also begin, which will further increase profit growth. If early-stage clinical drugs such as Relenopride, SKL13865, SKL20540, SKL-PSY, and SKL24741, which are likely to be commercialized, receive approval, earnings estimates will be raised even higher." He set the target price for SK Biopharm at 150,000 KRW.

Over the past five days, individual investors have net purchased 2,252,102 shares of SK Biopharm, while foreigners and institutions have net purchased 49,327 shares and net sold 2,239,638 shares, respectively.

※ Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.